Browsing Category

Uncategorized

Articles Banking Featured News Infographics Past Conference Upcoming conference Webinar

Biomimetic Innovations Ltd announces First-in-Human application of OsStic™ Injectable Synthetic Bone Void Filler

2026-08-12T12:30:00Z

SHANNON, Ireland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed - an Irish medical device company specialising in biomimetic materials, today announced the successful...

Mapi Pharma Announces Initial Phase I/IIa Clinical Results Supporting Continued Development of Once-Monthly Cariprazine Depot

2026-08-12T12:30:00Z

NESS ZIONA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced initial clinical...

Tris Pharma Expands Support for People Living with ADHD Through New Partnerships with Calm Health and ADHD Central

2026-08-12T12:30:00Z

Initiatives Provide New DYANAVEL® XR Patients With Digital Wellness Resources and Practical Organization Tools Designed to Support ADHD Care Beyond Medication

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

2026-08-12T12:30:00Z

Dyadic to host earnings call on August 12 at 5:00 pm ET

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

2026-08-12T12:30:00Z

Contrasting Science with Revolution Medicines and Erasca

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

2026-08-12T12:30:00Z

Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances

Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes

2026-08-12T12:30:00Z

Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell expertise through a research collaboration with Avaí Bio and Austrianova’s JV Company, Insulinova, aimed at advancing an...

SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

2026-08-12T12:25:00Z

TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused...

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

2026-08-12T12:15:00Z

Final histology and laboratory analyses support the study’s safety and performance objectives

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

2026-08-12T12:05:00Z

Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY™

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

2026-08-12T12:00:00Z

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

2026-08-12T12:00:00Z

PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including T1D, and...

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

2026-08-12T12:00:00Z

HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies...

MUHC Foundation President and CEO Marie-Hélène Laramée appointed to Women’s Health Collective Canada Board of Directors

2026-08-12T12:00:00Z

Laramée’s appointment strengthens Quebec’s voice in the national movement to close gaps in women’s health research, care, and leadership

Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026

2026-08-12T12:00:00Z

PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to the...

Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1

2026-08-12T12:00:00Z

Milestone strengthens manufacturing flexibility and supports pivotal study readiness

Reflect Scientific Reports More Than $1.4 Million in Freezer-System Sales to Biopharmaceutical Customers

2026-08-12T12:00:00Z

OREM, Utah, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF) today announced more than $1.4 million in delivered commercial freezer-system sales to six biopharmaceutical companies during the...

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

2026-08-12T12:00:00Z

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has...

ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments

2026-08-12T12:00:00Z

– Ying Huang, Ph.D. appointed to Board of Directors, bringing deep experience spanning executive public biotech leadership, Wall Street and big pharma R&D –

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

2026-08-12T11:30:00Z

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

2026-08-12T11:30:00Z

Record second quarter 2026 revenue increased 35% to $17.1 million, compared with Q2 2025

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

2026-08-12T11:30:00Z

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

2026-08-12T11:30:00Z

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been...

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

2026-08-12T11:30:00Z

Initiated global PERFORMA Phase 3 trial in MASH

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2026-08-12T11:30:00Z

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026

Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality

2026-08-12T11:12:02Z

COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness...

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

2026-08-12T11:08:47Z

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

2026-08-12T11:05:00Z

– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

2026-08-12T11:05:00Z

REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare...

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2026-08-12T11:00:00Z

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028

Re-wiring financial services operations for a bold future

Balancing Control, Cost and Innovation: What’s at Stake When Systems Fall Behind

India’s GST 2.0 Reform Sparks Surge in Consumer Spending & Auto…

Financing Social Good – What the RBC Social Finance Initiative Has…

Uncategorized